We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Turning Stem Cells from Fat into Blood Vessels

By LabMedica International staff writers
Posted on 13 Aug 2012
Autologous adult stem cells extracted via liposuction from fat tissue can provide the raw materials for growing tissue-engineered blood vessel (TEBV) in the lab, according to a new study.

Researchers at the University of Oklahoma (Norman, USA) first differentiated adipose-derived stem cells into smooth muscle cells (SMCs), and then seeded them onto a flat sheet of the human amniotic membrane--a very thin collagen membrane--used as a biological substrate to fabricate the small-diameter TEBVs. More...
To develop a tubular construct similar to that of a muscular artery's tunica media layer, the cell-seeded sheet was wrapped around a 3-mm removable mandrel with six to seven revolutions. After a two-week static culture period, the fabricated TEBV was assessed for biochemical and mechanical properties.

The researchers examined and compared the contraction of the vessel in response to carbachol--a specific agonist for SMCs--to that of porcine coronary arteries; burst pressure and elastic modulus tests were also conducted. The researchers found that the thickness and architecture of the engineered vessel matched that of a porcine coronary artery in a histological analysis; it also performed better than the porcine vessel for elasticity in a tensile strength test. However, the burst pressure was too low, at about 150 mm Hg, while native tissue withstands 1,000 mm Hg. The problem, according to the researchers, appeared to be that the layers of the rolled-up vessel are not adhering well to one another.

The researchers found that the mechanical integrity of the construct could be further improved by exposure to appropriate physiological conditions in a perfusion bioreactor, and that adipose-derived endothelial cells also could be seeded into the lumen of the construct to prevent platelet adhesion. The study was presented at the American Heart Association Basic Cardiovascular Sciences 2012 scientific sessions, held during July 2012 in New Orleans (LA, USA).

“These liposuction-derived vessels, grown in a lab, could help solve major problems associated with grafting blood vessels from elsewhere in the body or from using artificial blood vessels that are not living tissue,” concluded lead author and study presenter Matthias Nollert, PhD, and colleagues of the school of chemical, biological, and materials engineering. “Our engineered blood vessels have good mechanical properties and we believe they will contract normally when exposed to hormones.”

Related Links:

University of Oklahoma




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.